• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    5/9/23 9:06:45 AM ET
    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • TScan Therapeutics (NASDAQ:TCRX) stock rose 61.8% to $3.64 during Tuesday's pre-market session. The company's market cap stands at $89.6 million.
    • Erytech Pharma (NASDAQ:ERYP) stock increased by 47.49% to $1.18. The company's market cap stands at $36.5 million.
    • Ensysce Biosciences (NASDAQ:ENSC) stock increased by 42.15% to $4.89. The market value of their outstanding shares is at $6.2 million.
    • Synlogic (NASDAQ:SYBX) stock moved upwards by 23.21% to $0.69. The company's market cap stands at $46.7 million.
    • Novavax (NASDAQ:NVAX) shares rose 20.93% to $9.01. The company's market cap stands at $776.4 million. As per the press release, Q1 earnings came out today.
    • Tactile Systems Tech (NASDAQ:TCMD) stock rose 17.12% to $21.95. The company's market cap stands at $509.9 million. As per the press release, Q1 earnings came out yesterday.

    Losers

    • Enanta Pharma (NASDAQ:ENTA) stock decreased by 30.3% to $23.93 during Tuesday's pre-market session. The company's market cap stands at $499.8 million. As per the press release, Q2 earnings came out yesterday.
    • Lexaria Bioscience (NASDAQ:LEXX) shares decreased by 27.81% to $0.74. The company's market cap stands at $4.4 million.
    • AdaptHealth (NASDAQ:AHCO) shares decreased by 20.05% to $9.65. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today.
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) shares declined by 16.66% to $0.8. The company's market cap stands at $7.2 million.
    • Coherus BioSciences (NASDAQ:CHRS) shares fell 15.85% to $6.85. The market value of their outstanding shares is at $551.7 million. The company's, Q1 earnings came out yesterday.
    • Acorda Therapeutics (NASDAQ:ACOR) stock declined by 15.39% to $0.74. The market value of their outstanding shares is at $18.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AHCO
    $BLCM
    $CHRS

    CompanyDatePrice TargetRatingAnalyst
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Tactile Systems Technology Inc.
    $TCMD
    1/5/2026$35.00Neutral → Overweight
    Piper Sandler
    Enanta Pharmaceuticals Inc.
    $ENTA
    11/14/2025Overweight
    Analyst
    TScan Therapeutics Inc.
    $TCRX
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    Tactile Systems Technology Inc.
    $TCMD
    11/4/2025$28.00Neutral → Buy
    BTIG Research
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    Tactile Systems Technology Inc.
    $TCMD
    10/3/2025$23.50Buy
    Lake Street
    Enanta Pharmaceuticals Inc.
    $ENTA
    10/1/2025$20.00Hold → Buy
    Jefferies
    More analyst ratings

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (

    3/4/26 7:00:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, c

    3/3/26 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Jacobs John C converted options into 150,167 shares and covered exercise/tax liability with 69,288 shares, increasing direct ownership by 98% to 225,680 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:03:17 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, CFO and Treasurer Kelly James Patrick converted options into 43,167 shares and covered exercise/tax liability with 20,850 shares, increasing direct ownership by 22% to 124,280 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:04:04 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Chief Strategy Officer O'Hara Elaine converted options into 56,334 shares and covered exercise/tax liability with 22,429 shares, increasing direct ownership by 34% to 134,642 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    3/5/26 6:02:23 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    2/27/26 4:01:18 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Large owner Lynx1 Capital Management Lp bought $73,552 worth of shares (81,732 units at $0.90) and bought $71,974 worth of shares (80,069 units at $0.90) (SEC Form 4)

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    12/23/25 6:17:28 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tactile Systems upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Tactile Systems from Neutral to Overweight and set a new price target of $35.00

    1/5/26 8:37:29 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Enanta Pharmaceuticals

    Analyst initiated coverage of Enanta Pharmaceuticals with a rating of Overweight

    11/14/25 11:26:32 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    SEC Filings

    View All

    SEC Form S-8 filed by TScan Therapeutics Inc.

    S-8 - TScan Therapeutics, Inc. (0001783328) (Filer)

    3/4/26 7:42:13 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by TScan Therapeutics Inc.

    10-K - TScan Therapeutics, Inc. (0001783328) (Filer)

    3/4/26 7:30:55 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

    3/4/26 7:15:28 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Financials

    Live finance-specific insights

    View All

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Business Highlights Set patient census records for Sleep Health, Respiratory Health, and Wellness at Home, and a patient retention record for Diabetes Health. Acquired a leading HME provider in Hawaii, expanding the Company's geographic footprint to its 48th State and establishing operations to support the Company's new key capitated contract. Made signif

    2/24/26 7:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

    – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief

    11/6/25 1:54:45 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AHCO
    $BLCM
    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

    SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

    11/14/24 4:40:57 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

    SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

    11/14/24 4:40:11 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care